Apollo Therapeutics
PrivateLast Round
Series C
Extension
Dec 1, 2023
Est. Valuation
$246.75M
Total Funding Raised
$462M
Company Overview
Apollo Therapeutics is a biopharmaceutical company that translates fundamental medical research into innovative medicines by developing a diverse portfolio of pre-clinical and clinical-stage assets in oncology, inflammatory disorders, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apollo Therapeutics Comparables
Compare Apollo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Orange Grove Bio | 77% | |
| Eli Lilly and Company | 77% | |
| PureTech Health | 70% |
Apollo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 1, 2023 | ||||
| Series C | Sep 6, 2023 | ||||
| Series B | Jun 17, 2021 | ||||
| Seed | Jan 25, 2016 |
Apollo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IP Group | Series B |
| Patient Square Capital | Series C Extension, Series C, Series B |
| Reimagined Ventures | Series B |
| Imperial College London | Seed |
| M&G Investments | Series C |
| Imperial Innovations | Seed |
| University College London | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 5, 2025
Developing a monoclonal antibody treatment for pulmonary arterial hypertension (PAH).
- May 5, 2025
Collaborating with Imperial College London on new antibody treatment.
Apollo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Apollo Therapeutics's valuation, stock price, and market status.
Is Apollo Therapeutics a public or private company?
Apollo Therapeutics is a private company.
What is the current stock price of Apollo Therapeutics?
Apollo Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Apollo Therapeutics worth (valuation)?
Apollo Therapeutics's valuation is estimated at $246.8M based on funding round data.
Can I buy Apollo Therapeutics stock?
Apollo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Apollo Therapeutics's last funding round?
Apollo Therapeutics's most recent funding round was Series C Extension on June 17, 2021.
Who are the main investors in Apollo Therapeutics?
Key investors in Apollo Therapeutics include Patient Square Capital.
Will Apollo Therapeutics IPO soon?
No public IPO plans have been announced for Apollo Therapeutics.
How can I track Apollo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Apollo Therapeutics's secondary market activity and sign up for updates.